Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Withdrawal
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Withdrawal due to treatment-related adverse effects 0/35 (0%) with betaxolol plus digoxin 0/35 (0%) with diltiazem plus digoxin	Significance not assessed
Dizziness
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Dizziness 2/35 (6%) with betaxolol plus digoxin 2/35 (6%) with diltiazem plus digoxin	Significance not assessed
Dyspnoea
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Dyspnoea 3/35 (9%) with betaxolol plus digoxin 0/35 (0%) with diltiazem plus digoxin	Significance not assessed
Gastric pain
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Gastric pain 2/35 (6%) with betaxolol plus digoxin 1/35 (3%) with diltiazem plus digoxin	Significance not assessed
Headache
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Headache 1/35 (3%) with betaxolol plus digoxin 2/35 (6%) with diltiazem plus digoxin	Significance not assessed
Fatigue
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Fatigue 3/35 (9%) with betaxolol plus digoxin 1/35 (3%) with diltiazem plus digoxin	Significance not assessed
Nausea
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Nausea 2/35 (6%) with betaxolol plus digoxin 2/35 (6%) with diltiazem plus digoxin	Significance not assessed
Constipation
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Constipation 1/35 (3%) with betaxolol plus digoxin 0/35 (0%) with diltiazem plus digoxin	Significance not assessed
Oedema
RCT Crossover design	35 people, mean age 52 years with chronic atrial fibrillation of >1 month In review	Oedema 1/35 (3%) with betaxolol plus digoxin 0/35 (0%) with diltiazem plus digoxin	Significance not assessed